Pharmatest brings new osteoarthritis research models to ASBMR Houston
Press Release | Pharmatest Services Ltd
SEPTEMBER 02, 2014
Turku, Finland: – Oncology and skeletal disease specialist CRO Pharmatest Services will present several innovative research models targeting osteoarthritis (OA) when it appears at next month’s Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) in Texas.
Pharmatest will be an exhibitor at the four-day meeting, which takes place in Houston on September 12 – 15, 2014. The ASBMR meeting is widely recognized at the world’s foremost event in bone research.
This year Pharmatest attends ASBMR with three scientific presentations that demonstrate development of its latest research models for osteoarthritis research. The models described in the presentations were developed in a project funded by the EUREKA Eurostars programme and can be used for testing efficacy of customer compounds for osteoarthritis treatment.
Influential preclinical models
Jussi Halleen, CEO of Pharmatest, has paid tribute to the work of collaboration partner Percuros BV, a biotech company based in Leiden, Netherlands, for its contribution to the research and also to the Eurostars programme for the funding.
“I am convinced that these models will play a positive and influential role in helping the life sciences industries in developing new OA treatments and battling the increasing disease burden of this crippling disease in the years ahead,” said Mr. Halleen.
Visitors to the Pharmatest stand at Booth 220 will be able to gain in depth insights into the organization’s latest work and advances in developing preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases.
Pharmatest is accepting advance notifications to schedule meetings with our representatives at the ASBMR event. Those interested should email Pharmatest at firstname.lastname@example.org
Pharmatest Services Ltd (Pharmatest) is a contract research organisation (CRO) specializing in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.
Pharmatest helps establish proof-of-efficacy of cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.
Headquartered in Turku, Finland, Pharmatest’s preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.
The CRO has supported close to 100 clients from pharmaceutical and biotechnology organizations worldwide in research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.
Pharmatest has developed a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with maximum efficiency and providing clients with access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.
About ASBMR 2014
The American Society for Bone and Mineral Research is one of the world’s leading professional, scientific and medical organizations for bone and mineral researchers and clinicians and forms a highly-effective voice for advocacy and science policy for nearly 4,000 scientists and clinicians from 60 countries.
The society’s annual meeting attracts leading scientists, researchers and laboratories from around the globe to exchange latest scientific insights, connect with colleagues and learn about leading edge products and services.
The 2014 meeting will be held September 12-15 at Houston’s George R. Brown Convention Center and will feature more than 100 presentation and discussion sessions, including ‘Meet-the-Professor’ events, plenary presentations and topical symposia.
Sessions of Interest include Plenary Lectures on osteoimmunology from Dr. Hiroshi Takayanagi of University of Tokyo and on selective autophagy, presented by Dr. Ana Maria Cuervo, of the Albert Einstein College of Medicine.
The 2014 conference will also break new ground in beingwebcast via ASBMR 2014 Annual Meeting – Live Online, ASBMR’s inaugural virtual conference experience.
More information available at http://www.asbmr.org/annual-meeting
Jussi Halleen; CEO, Pharmatest Services Ltd.
Tel.: + 358 50 380 9551
Andrew Heiniluoma US Sales Representative, Pharmatest
Tel: +1 978 340 1028
Click on Pharmatest brings new osteoarthritis research models to ASBMR Houston for other information.
Click on Skeletal Disease Models for more information on Pharmatests research models.
Click on Pharmatest to contact the company directly.